Commences Global Cannabis Research Partnership Campaign

NANOOSE BAY, BC, Feb. 7, 2023 /PRNewswire/ – Protonify Corporation (“Protonify” or the “Company“), a leading global provider of high purity cannabinoid ingredients (www.protonify.com), is pleased to announce the launch of a Global Cannabinoid Research Partnership Campaign designed to engage the world’s leading researchers investigating the medicinal and therapeutic efficacy of delta-9-THC and THCA.

Under this new program, Protonify will provide cannabis researchers with complimentary access to its unique, high-purity, pharmaceutical-grade cannabinoid ingredients including THC concentrate (96%+ purity) and our industry-leading THCA isolate that has proven stability in an odorless, tasteless powder format and purity levels that approach 100%. These products are produced with Protonify’s patent-pending, organic chemistry-based process that is unlike any other cannabis extraction technique being used today. The process results in consistent, high-purity products that set the bar for clinical cannabinoid research.

“One of the greatest challenges that cannabis researchers face is the lack of consistent, high-quality cannabinoid inputs”, said Andrew Fisher, CEO of Protonify. “Cannabinoid ingredients that have been sourced from traditional cannabis extractors contain high levels of unknown impurities, are unstable, and critically, have different profiles from one batch to the next. Protonify solves these problems.  We look forward to sharing our quality products with teams seeking to effectively advance global cannabinoid research.”

THCA Isolate: THCA is rapidly becoming one of the most widely discussed cannabinoids in research today. To date, clinical application of THCA has been complicated by its instability, as it readily converts into THC. Protonify solves this problem with a proven, stable product that is perfect for robust clinical studies. Research to date has uncovered many potential benefits that include anti-inflammatory, antioxidant, antiemetic, analgesic and as a neuroprotective, without the unwanted psychoactive effects of THC.

Pure THC Concentrate: The bulk of today’s botanical THC concentrates utilize traditional distillate-based processes which produce products that are limited to purity levels of about 90%. In addition to the high-level of impurities, and as a consequence of the distillation process, artifacts and isomers of the desired delta-9-THC molecule are created which negatively impact product quality, consistency, taste, user experience, safety, among other factors. Protonify offers a unique pathway to delta-9-THC that eliminates the many impurities that are associated with the distillation process.

Interested partners should contact Protonify at [email protected]. Third-party licensed laboratory certificates of analysis (“COAs”) are available upon request.

About Protonify Corporation

Protonify Corporation is a privately-held, Canadian-licensed global B2B manufacturer of botanically-derived pharmaceutical-grade cannabinoid isolates of the highest purity. Protonify’s cannabinoids are non-synthetic, odorless and approach 100% purity. Available in several formats, including dry powder and nano-encapsulated, the cannabinoids fit seamlessly into traditional CPG formulations, industrial scale production lines and supply chains, and are the perfect foundation to enable cannabis product formulators and manufacturers to safely and reliably build brand affinity for consumer packaged goods containing THC and THCA.  Manufacturing of Protonify ingredients follow Good Manufacturing Practices (GMP) for extracted products, aligning with existing GMP / ISO / HACCP standards, and are the foundation for the next generation of cannabis-infused, high purity medicinal products.

For more information, please visit www.protonify.com.

SOURCE Protonify Corporation

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Photo: Marshawn Lynch with a cloud of smoke. (Photo: Courtesy of Dodi Blunts)

Former Raiders running back Marshawn Lynch is going into “Beast Mode” again. This time his efforts have a different focus: launching his new brand of “diamond-infused” marijuana products, Dodi Blunts. For those who might wonder, “dodi” is a slang term that refers to high-quality cannabis. Dodi users will experience the highest, richest potency from palm leaf-wrapped blunts infused with THCa diamonds presented in a reusable blunt tube.

According to an article in the East Bay Times, the former Raiders running back will be partnering with recently founded 2nd and Goal Ventures, a corporation out of Toronto, Canada. Jeff Goldenberg, a founder of 2nd and Goal Ventures, has worked in “white label” marijuana products in Canada, creating products for license holders to sell on their own.

Goldenberg explains that the THCa diamonds are a form of extract from the cannabis plant, and they are the most potent at around 99 percent THC, which is the psychoactive chemical found in marijuana. But don’t worry about getting too high, Dodi’s Blunts won’t be that strong since the diamonds are infused into traditional cannabis flower inside the palm leaf wrap.

Lynch is not new to utilizing his NFL image and getting involved with Culture-focused business ventures. He see’s Dodi Blunts as an investment opportunity that “has the ability to raise up Black and Brown communities — and I intend to lift up those who I can.”

The blunts will launch in March at 24 select dispensaries in the San Francisco Bay Area, and Dodi Blunts plans to expand to more cannabis products thereafter.